NephroNet

05/28/2026

🧠💊 Ticagrelor vs. Clopidogrel in Stroke Patients with CYP2C19 LOF — Age & Kidney Function Matter

Objective:
Compare efficacy and safety of ticagrelor-aspirin vs. clopidogrel-aspirin in CYP2C19 loss-of-
function carriers with stroke, stratified by age and renal function.

Study details:
Data from CHANCE-2 trial.
Primary endpoint: new stroke within 90 days.
Safety endpoint: bleeding events.
Stratification by age (90 mL/min/1.73 m²
Mild impairment: eGFR 60–89
Moderate/severe impairment: eGFR 90):
Ticagrelor significantly reduced stroke risk in both ≥65 years (HR 0.53, p = 0.008) and

05/26/2026

🥦 What’s your go-to kidney-friendly food or healthy snack?

05/25/2026

United in remembrance. Stronger together.

05/22/2026

Proof That No Summit Is Too High After Transplant

After receiving a kidney transplant from his father in 2022, Pemba Sherpa—a 37-year-old from Nepal—refused to let chronic illness define his future. Determined to show what’s possible after transplant, he trained relentlessly and, in May 2025, became the first kidney transplant recipient to su...

05/21/2026

Empowering Kidney Care, One Episode at a Time!

Subscribe to the podcast today!

05/18/2026

Clinical Trials for Pig-to-Human Kidney Transplantation Are Here. From Research to Real-World Impact!
https://ow.ly/iaSQ50WCeOB

05/14/2026

🩺 Multi-Institutional Study on RAAS Inhibitor Use in Pediatric Lupus

Purpose:
Evaluate the potential of a pediatric learning health system to conduct large-scale, comparative effectiveness research in pediatric-onset systemic lupus erythematosus (SLE).
Focus on RAAS inhibitor use, treatment indications, and outcomes (hypertension & proteinuria).

Study design & population:
Data from 6 PEDSnet institutions.
1,303 pediatric SLE patients (457 with lupus nephritis, LN).
Control group: 200 non-SLE patients per site from the same clinics.

Key data metrics collected:
% of encounters with blood pressure (BP) readings.
% of BP readings paired with height (for accurate pediatric BP assessment).
% of patients with urinalysis within 7 days of SLE diagnosis.
Ability to classify proteinuria as normal/abnormal.
RAAS inhibitor prescription rates and timing.

Results:
BP recorded at 62% of encounters; 96% paired with a height.
Higher BP levels in SLE/LN patients vs. controls.
~1/3 of SLE patients diagnosed with hypertension.
60%-83% had urinalysis protein measurement within 7 days of diagnosis.
Proteinuria classification possible in 96% of tests; nearly all LN patients had ≥1 abnormal result
(94%-100%).
RAAS inhibitor use:
31% of SLE patients.
71% of LN patients (site range: 60%-84%).
90% of SLE cases starting RAAS inhibitors had hypertension, elevated BP, or proteinuria at
initiation.

Conclusions & implications:
Pediatric learning health systems can reliably capture key clinical data for lupus research.
Identified hospital-level variation in RAAS inhibitor use, signaling potential for treatment
standardization.
Supports more efficient multi-institutional comparative effectiveness studies in pediatric lupus.

🔗 Read more: https://pubmed.ncbi.nlm.nih.gov/40393065/

05/12/2026

💊 Breakthrough in Lupus Nephritis Treatment!

Results from the REGENCY phase 3 trial show that adding obinutuzumab to standard therapy significantly improved kidney outcomes in adults with active lupus nephritis.
🔹 Complete renal response at week 76:
✔️ 46.4% with obinutuzumab vs. 33.1% with placebo (📈 P = 0.02)
🔹 Better outcomes on lower steroid doses
🔹 Improved protein-to-creatinine ratios
🔹 No unexpected safety concerns
These findings support obinutuzumab as a promising addition to lupus nephritis treatment. 🧬
🔗 Read more: https://ow.ly/7SiL50YTewz

05/08/2026

A dual GLP-1 & glucagon receptor agonist, significantly reduced urinary albumin-to-creatinine ratio (UACR) in patients w/ type 2 diabetes & chronic kidney disease. At 14 weeks, reductions reached ~44% w/ 300 μg & ~50% with 600 μg versus placebo, w/ effects sustained at 26 weeks.

05/07/2026

🌟 The Future of Nephrology: Innovation, Precision, and Patient-Centered Care 🌟

Nephrology is entering a transformative era — where cutting-edge science meets personalized medicine. Here are some of the biggest trends shaping kidney health today:

🔬 1. Precision Medicine in Kidney Disease
Genetic testing and molecular profiling are helping tailor treatments for conditions like IgA nephropathy and polycystic kidney disease, moving away from one-size-fits-all approaches.

💉 2. Advanced Therapies & Biologics
New drugs targeting the complement pathway and inflammation are showing promise in clinical trials, offering hope for slowing disease progression.

🧪 3. Next-Generation Diagnostics
Tools like metagenomic next-generation sequencing (mNGS) are enabling faster, more accurate detection of infections in dialysis patients — leading to earlier and more targeted interventions.

📊 4. Data-Driven Care & AI
Artificial intelligence is being used to predict acute kidney injury risk, optimize dialysis schedules, and analyze massive datasets for treatment outcomes.

🌱 5. Whole-Patient Wellness
Lifestyle interventions — from plant-based diets to integrated cardiovascular care — are taking center stage, recognizing the close link between kidney and heart health.

💡 Why it matters:
These trends are not just about technology — they’re about giving patients longer, healthier lives and empowering clinicians with tools to make faster, smarter decisions.

Let’s continue to support innovation, advocate for early detection, and push forward the future of kidney care.